PPAR与胰岛素抵抗  

PPAR and insulin resistance

作　　者：丁世英[1] 申竹芳[1] 谢明智[1] 

机构地区：[1]中国医学科学院.中国协和医科大学药物研究所,北京100050

出　　处：《中国药理学通报》2002年第3期241-245,共5页Chinese Pharmacological Bulletin

基　　金："九五"国家攀登计划预选项目资助 No 970 2 110 18

摘　　要：PPAR即过氧化物酶体增殖物激活受体 ,是核受体超家族成员之一 ,它可以促进脂肪细胞分化 ,在脂肪代谢中起重要作用。近年来随着对胰岛素增敏剂噻唑烷二酮 (TZD)类药物作用机制的深入研究 ,发现PPARγ是该类药物的主要功能受体 ,于是展开了对于PPAR与胰岛素抵抗之间关系的研究。TZD类药物激活PPARγ ,可以改善胰岛素抵抗 ,而在基因敲除的PPARγ+ / -中 ,却发现胰岛素敏感性增加。所以 ,PPAR激活与改善胰岛素抵抗之间不是简单的正相关关系。对二者关系的进一步明确 。Peroxisome proliferator activated receptor(PPAR), a member of the hormone receptor superfamily, is a key regulating factor in adipocyte differentiation and lipids metabolism. Recently, with the increased understanding of the precise mechanisms of TZD, thiazolidinedione class of insulin sensitizer, PPARγ has also been identified as the major functional receptor for the drugs. In the study of the relationship between PPAR and insulin resistance, considerable gaps appeared. TZD induced activation of PPARγ is known to promote insulin sensitivity. More interestingly, however, PPARγ +/- heterozygous mice were shown to be less susceptible to insulin resistance. These findings suggest that the relationship between PPAR activation and insulin sensitivity improvement is not simplely positively related. A better understanding of the role of PPAR in insulin action system will be critical in developing more efficacious and safe agents that act on PPAR and benefit patients with type 2 diabetes.

关 键 词：PPAR 胰岛素抵抗 噻唑烷二酮类 Ⅱ型糖尿病 

分 类 号：R587[医药卫生—内分泌] R329.24[医药卫生—内科学]